REG - AstraZeneca PLC - Director/PDMR Shareholding

AstraZenecaAnnouncement

01/08/2022 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220801:nRSA4400Ua&default-theme=true

RNS Number : 4400U  AstraZeneca PLC  01 August 2022

1 August 2022 15:05 BST

 

 

Transaction by Person Discharging Managerial Responsibilities

 

AstraZeneca PLC (the Company) announced that on 29 July 2022 awards of
AstraZeneca American Depositary Shares (ADSs) vested to Dr Aradhana Sarin,
Executive Director and Chief Financial Officer. Each ADS represents one half
of an Ordinary Share of $0.25 in the Company.

 

In accordance with the Agreement and Plan of Merger between the Company and
Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's in-flight share awards
granted by Alexion were converted to 2017 Incentive Plan.

 

Following the withholding of awards over AstraZeneca ADSs under the
AstraZeneca Global Restricted Stock Plan at the time of closing of the Alexion
acquisition. The awards that vested on 29 July 2022 replaced in-flight Alexion
awards originally granted to Dr Sarin between February 2019 and February 2021
under the Alexion shares to satisfy certain tax obligations arising on
vesting, 67,523 ADSs vested.

 

For tax purposes, the fair market value of an ADS at vest of the awards was
US$66.72, being the closing price on the last trading day preceding the
vesting.

 

Further details are set out in the attached notification, made in accordance
with the requirements of the EU Market Abuse Regulation (as it forms part of
UK law pursuant to the European Union (Withdrawal) Act 2018.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Aradhana Sarin

 2    Reason for the notification

 a)   Position/status                                              Chief Financial Officer

 b)   Initial notification/Amendment                               Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         AstraZeneca PLC

 b)   LEI                                                          PY6ZZQWO2IZFZC3IOL08

 4i   Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument  AstraZeneca PLC American Depositary Shares

      Identification code

                                                                   CUSIP: 046353108

 b)   Nature of the transaction                                    Acquisition of AstraZeneca PLC American Depository Shares pursuant to a

                                                            vesting under the Global Restricted Stock Plan

 c)   Price(s) and volume(s)

Price(s)  Volume(s)
                                                                   0    67,523
 d)   Aggregated information                                       Not applicable - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      29 July 2022

 f)   Place of the transaction                                     Outside a trading venue

d)

 

Aggregated information

 

- Aggregated volume

- Price

Not applicable - single transaction

 

 

 

 

e)

 

Date of the transaction

 

29 July 2022

f)

 

Place of the transaction

 

Outside a trading venue

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAOKRURUWRRR